SBFM Q3 2022 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$132,808+163.6% YoY

Gross Profit

$67,02550.5% margin

Operating Income

-$2M-1293.6% margin

Net Income

-$1M-1097.1% margin

EPS (Diluted)

$-160.00

QoQ Revenue Growth

-11.6%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$41M

Total Liabilities

$480,209

Stockholders' Equity

$40M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132,808	$50,376	+163.6%
Gross Profit	$67,025	$30,870	+117.1%
Operating Income	-$2M	-$496,000	-246.4%
Net Income	-$1M	-$4M	+63.9%